“New trials and results in systemic treatment of HCC”
The design of prospective trials in hepatocellular carcinoma (HCC) is a true challenge since the underlying condition of the liver, upon drug exposure, could interact with the specific course of carcinoma and influence overall outcome. The information generated by basic and clinical researchers provides the rationale for improving the prognosis of this complex disease. However, an additional level of challenge relies in the capacity to interpret in real time the emerging new data in order to integrate them in the design of further trials. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 10, 2018 Category: Gastroenterology Authors: Mar ía Reig, Leonardo Gomes da Fonseca, Sandrine Faivre Tags: Clinical Trial Watch Source Type: research

Long noncoding RNA LncHand2 promotes liver repopulation via c-Met signaling
The liver is a central organ for homeostasis with considerable regenerative capacity [1 –3]. Liver transplantation is the only effective therapy for advanced liver disease. However, a shortage of donor organs is a real problem across the world. Hepatocyte cell therapy is thus an attractive alternative to liver transplantation. Mature hepatocytes harbor a remarkable capacity to prolif erate upon liver injury [4]. Liver regeneration surely occurs after the loss of hepatic tissue as a fundamental parameter. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 10, 2018 Category: Gastroenterology Authors: Yanying Wang, Pingping Zhu, Jing Wang, Xiaoxiao Zhu, Jianjun Luo, Shu Meng, Jiayi Wu, Buqing Ye, Luyun He, Ying Du, Lei He, Runsheng Chen, Yong Tian, Zusen Fan Source Type: research

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. In this context, the panel of experts, having emphasised the importance of initiating aetiologic treatment for any degree of hepatic disease at the earliest possible stage, extended its work to all the complications of cirrhosis, which had not been covered...
Source: Journal of Hepatology - April 10, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

“New trials and results in systemic treatment of HCC”
The design of prospective trials in hepatocellular carcinoma (HCC) is a true challenge since the underlying condition of the liver, upon drug exposure, could interact with the specific course of carcinoma and influence overall outcome. The information generated by basic and clinical researchers provides the rationale for improving the prognosis of this complex disease. However, an additional level of challenge relies in the capacity to interpret in real time the emerging new data in order to integrate them in the design of further trials. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 10, 2018 Category: Gastroenterology Authors: Mar ía Reig, Leonardo Gomes da Fonseca, Sandrine Faivre Tags: Clinical Trial Watch Source Type: research

Long noncoding RNA LncHand2 promotes liver repopulation via c-Met signaling
The liver is a central organ for homeostasis with considerable regenerative capacity [1 –3]. Liver transplantation is the only effective therapy for advanced liver disease. However, a shortage of donor organs is a real problem across the world. Hepatocyte cell therapy is thus an attractive alternative to liver transplantation. Mature hepatocytes harbor a remarkable capacity to prolif erate upon liver injury [4]. Liver regeneration surely occurs after the loss of hepatic tissue as a fundamental parameter. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 10, 2018 Category: Gastroenterology Authors: Yanying Wang, Pingping Zhu, Jing Wang, Xiaoxiao Zhu, Jianjun Luo, Shu Meng, Jiayi Wu, Buqing Ye, Luyun He, Ying Du, Lei He, Runsheng Chen, Yong Tian, Zusen Fan Source Type: research

Reply to: “Primed for the spotlight: Transplantation for alcohol-associated liver disease”
We appreciate the comments by Dr. Im and agree fully with the issues raised, including the negative effect terms like “alcoholic” and “recidivism” have on society’s view of alcohol-related diseases. Similarly, we too endorse the need for more research aimed at optimizing candidate selection for liver transplantation in patients with severe alcohol-related hepatitis. It was emphasized both in Dr Im’s let ter and our editorial that fears about the impact of offering donated liver allografts to those with severe alcohol-related hepatitis – that i) donors would be discouraged by the po...
Source: Journal of Hepatology - April 9, 2018 Category: Gastroenterology Authors: Jay Luther, Jules L. Dienstag Tags: Letter to the Editor Source Type: research

A measure of alcohol consumption in late adolescence associated with liver disease after 39  years of follow-up is insufficient to guide alcohol safe limits
We have read with great interest the paper by Hagstr öm et al.1 and the associated editorial by Louvet and Krag2 which uses a prospective cohort design to examine the association between a single measure of alcohol consumption and subsequent risk of severe liver disease over a follow-up period of 39 years. The study is based on data on alcohol, smo king, BMI, and other factors collected at conscription to military service for 43,000 Swedish men, 18–20 years of age. Follow-up to ascertain a diagnosis of severe liver disease was done by linkage to registries. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 9, 2018 Category: Gastroenterology Authors: G. Askgaard, J.S. Tolstrup, D.A. Leon Tags: Letter to the Editor Source Type: research

EASL Recommendations on Treatment of Hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 9, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

Reply to: “Primed for the spotlight: Transplantation for alcohol-associated liver disease”
We appreciate the comments by Dr. Im and agree fully with the issues raised, including the negative effect terms like “alcoholic” and “recidivism” have on society’s view of alcohol-related diseases. Similarly, we too endorse the need for more research aimed at optimizing candidate selection for liver transplantation in patients with severe alcohol-related hepatitis. It was emphasized both in Dr Im’s let ter and our editorial that fears about the impact of offering donated liver allografts to those with severe alcohol-related hepatitis – that i) donors would be discouraged by the po...
Source: Journal of Hepatology - April 9, 2018 Category: Gastroenterology Authors: Jay Luther, Jules L. Dienstag Tags: Letter to the Editor Source Type: research

A measure of alcohol consumption in late adolescence associated with liver disease after 39  years of follow-up is insufficient to guide alcohol safe limits
We have read with great interest the paper by Hagstr öm et al.1 and the associated editorial by Louvet and Krag2 which uses a prospective cohort design to examine the association between a single measure of alcohol consumption and subsequent risk of severe liver disease over a follow-up period of 39 years. The study is based on data on alcohol, smo king, BMI, and other factors collected at conscription to military service for 43,000 Swedish men, 18–20 years of age. Follow-up to ascertain a diagnosis of severe liver disease was done by linkage to registries. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 9, 2018 Category: Gastroenterology Authors: G. Askgaard, J.S. Tolstrup, D.A. Leon Tags: Letter to the Editor Source Type: research

EASL Recommendations on Treatment of Hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 9, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

EASL International Recognition Award Recipient 2018: Prof. Anna Lok
It is a great honor and pleasure to introduce Dr. Anna Suk-Fong Lok for the EASL International Recognition Award. This award is conferred to an individual with a history of distinguished academic achievements and substantial contributions to the field of hepatology. Like the declaration of fine wine vintages, this honor is only conferred when there is a truly exceptional recipient. As a former mentee and someone who has known Anna for the past 25  years I can attest that she is truly deserving of this award. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Authors: Marc G. Ghany Tags: Editorial Source Type: research

EASL Recognition Award Recipient 2018: Prof. Didier Samuel
On behalf of the European Association for the Study of the Liver, it is a great honor and privilege to present Prof. Didier Samuel as a recipient of EASL ’s 2018 Recognition Award. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Authors: Daniel Shouval Tags: Editorial Source Type: research

EASL Recognition Award Recipient 2018: Prof. Mario Mondelli
It is a great honor and pleasure for me to highlight the life and career of Mario Mondelli, who is receiving the European Association for the Study of the Liver Recognition Award for 2018. I have known Mario since 1980 when he was a research fellow with Professor Roger Williams at the Liver Unit, King ’s College School of Medicine& Dentistry, London, UK. Over the decades Mario has become a close colleague and a personal friend. We both share our passion and enthusiasm for liver diseases, in particular immunology in liver disease and clinical hepatology with an emphasis on viral hepatitis and immune mediated liver...
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Authors: Michael P. Manns Tags: Editorial Source Type: research

Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

EASL monothematic conference: Gut –liver axis, Leuven, Belgium, 2018
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

EASL NAFLD Summit 2018, Geneva, Switzerland
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

EASL clinical school: Abdominal sonography, Rotterdam, Netherlands, 2018
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

The International Liver CongressTM, Vienna, Austria, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

Contents
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

JHEP at a glance (May 2018)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

Discover the Hepahealth Project Report
(Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Source Type: research

From the Editor ’s desk....
An important study in the field of non-alcoholic fatty liver disease (NAFLD) highlights the association with systemic cardiovascular problems. More specifically, a large study by Lee et al. investigated the association between NAFLD and subclinical coronary atherosclerosis. A total of 5,121 consecutive asymptomatic individuals with no prior history of coronary artery disease underwent abdominal ultrasonography and coronary computed tomography angiography (CCTA). Thirty-eight percent of the participants had ultrasonography-diagnosed NAFLD. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Authors: Richard Moreau, Ramon Bataller, Thomas Berg, Jessica Zucman-Rossi, Rajiv Jalan Tags: Editorial Desk Source Type: research

Reply to: “A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits”
We thank Askgaard et al. for their comment on our recent paper on alcohol consumption early in life and subsequent risk of severe liver disease.1 We agree, and discuss in the paper, that the main limitation of the study is the single point measurement of alcohol consumption, with no data available on changes of alcohol consumption during life. We also agree that a likely explanation for the increased risk is because of continued and perhaps increased consumption. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 7, 2018 Category: Gastroenterology Authors: Hannes Hagstr öm, Tomas Hemmingsson, Andrea Discacciati, Anna Andreasson Tags: Letter to the Editor Source Type: research

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
The harmful use of alcohol has been estimated to cause approximately 3.3  million deaths every year, corresponding to nearly 6% of all deaths globally. Therefore, the effective management and treatment of alcoholic liver disease is a pertinent public health issue. In the following Clinical Practice Guidelines, the latest data on the treatment and management of alcohol- related liver disease will be reviewed and up to date recommendations for clinical management will be provided. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 5, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 5, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
The harmful use of alcohol has been estimated to cause approximately 3.3  million deaths every year, corresponding to nearly 6% of all deaths globally. Therefore, the effective management and treatment of alcoholic liver disease is a pertinent public health issue. In the following Clinical Practice Guidelines, the latest data on the treatment and management of alcohol- related liver disease will be reviewed and up to date recommendations for clinical management will be provided. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 5, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 5, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

Primed for the spotlight: Transplantation for alcohol-associated liver disease
I applaud the editorial by Kubiliun et al., entitled “Early liver transplantation for alcoholic hepatitis: Ready for primetime?” for its insightful examination of this controversial and emerging indication for liver transplantation (LT).1 I would like to highlight several issues. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 4, 2018 Category: Gastroenterology Authors: Gene Y. Im Tags: Letter to the Editor Source Type: research

May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
We read with interest the recent study by van Vugt et al.1 which adds data to the debate on a desirable improvement in the policy for the optimization of the organ allocation criteria in liver transplant (LT) setting. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 4, 2018 Category: Gastroenterology Authors: Cristina Lucidi, Barbara Lattanzi, Oliviero Riggio, Manuela Merli Tags: Letter to the Editor Source Type: research

Ammonia: This is not the end but rather the end of the beginning
Hepatic encephalopathy (HE) represents a wide spectrum of neurological or neuropsychological symptoms caused by liver disease and/or portosystemic shunts. The major role of hyperammonemia in association with systemic inflammation and oxidative stress in the pathogenesis of HE has progressively emerged. However, the cascading downstream effects caused by these pathogenic factors remain unresolved. The underlying abnormalities which are thought to cause HE include modification of glutamatergic and GABAergic neurotransmission, mitochondrial dysfunction, energy impairment, lactate dyshomeostasis, increased blood-brain barrier ...
Source: Journal of Hepatology - April 4, 2018 Category: Gastroenterology Authors: Nicolas Weiss, Gitte Dam, Christopher F. Rose Tags: Editorial Source Type: research

Primed for the spotlight: Transplantation for alcohol-associated liver disease
I applaud the editorial by Kubiliun et al., entitled “Early liver transplantation for alcoholic hepatitis: Ready for primetime?” for its insightful examination of this controversial and emerging indication for liver transplantation (LT).1 I would like to highlight several issues. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 4, 2018 Category: Gastroenterology Authors: Gene Y. Im Tags: Letter to the Editor Source Type: research

May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
We read with interest the recent study by van Vugt et al.1 which adds data to the debate on a desirable improvement in the policy for the optimization of the organ allocation criteria in liver transplant (LT) setting. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 4, 2018 Category: Gastroenterology Authors: Cristina Lucidi, Barbara Lattanzi, Oliviero Riggio, Manuela Merli Tags: Letter to the Editor Source Type: research

Ammonia: this is not the end but rather the end of the beginning
Hepatic encephalopathy (HE) represents a wide spectrum of neurological or neuropsychological symptoms due to liver disease and/or portosystemic shunts. The major role of hyperammonemia in association with systemic inflammation and oxidative stress has progressively emerged as key players in the pathogenesis of HE. However, the cascading downstream effects due to these pathogenic factors remain unresolved. The underlying abnormalities which have been described to cause HE include modification of glutamatergic and GABAergic neurotransmission, mitochondrial dysfunction, energy impairment, lactate dyshomeostasis, increased blo...
Source: Journal of Hepatology - April 4, 2018 Category: Gastroenterology Authors: N. Weiss, G. Dam, C.F. Rose Source Type: research

A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure
The standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAA). Although interferon-free DAA-based regimens are highly successful in the vast majority of patients with HCV infection, treatment is nevertheless unsuccessful in some patients. European Association for Study of Liver Recommendations 2016 recommend that retreatment be based on an interferon-free combination, including sofosbuvir (SOF) as a backbone (because of its higher barrier to resistance than other agents), plus one to three other DAAs, ideally with no cross-resistance with the previ...
Source: Journal of Hepatology - April 3, 2018 Category: Gastroenterology Authors: Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed I. Zanaty, Mohamed Ramadan Tags: Letter to the Editor Source Type: research

Has the time come for using MELD-Sarcopenia score?
We read with interest the article by van Vugt et al.1 which showed that while sarcopenia was associated with increased mortality on the transplant waiting list, its incorporation into the model for end stage liver disease score did not substantially add to the prediction of waiting list mortality. It was a well-designed study and the use of competitive risk analysis was particularly commendable given the nature of the cohort (patients on transplant waiting list). (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 3, 2018 Category: Gastroenterology Authors: Arka De, Akash Singh, Sunita Kumari, Virendra Singh Tags: Letter to the Editor Source Type: research

Reply to: “May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?” and “Has the time come for using MELD-Sarcopenia score?”
We would like to thank Lucidi et al.1 and De et al.2 for their interest in our work3 and for highlighting some challenging issues regarding the impact of low skeletal muscle mass in liver transplant candidates with cirrhosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 3, 2018 Category: Gastroenterology Authors: Jeroen L.A. van Vugt, Louise J.M. Alferink, S. Buettner, Herold J. Metselaar, Jan N.M. IJzermans Tags: Letter to the Editor Source Type: research

A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure
The standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAA). Although interferon-free DAA-based regimens are highly successful in the vast majority of patients with HCV infection, treatment is nevertheless unsuccessful in some patients. European Association for Study of Liver Recommendations 2016 recommend that retreatment be based on an interferon-free combination, including sofosbuvir (SOF) as a backbone (because of its higher barrier to resistance than other agents), plus one to three other DAAs, ideally with no cross-resistance with the previ...
Source: Journal of Hepatology - April 3, 2018 Category: Gastroenterology Authors: Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed I. Zanaty, Mohamed Ramadan Tags: Letter to the Editor Source Type: research

Has the time come for using MELD-Sarcopenia score?
We read with interest the article by van Vugt et al.1 which showed that while sarcopenia was associated with increased mortality on the transplant waiting list, its incorporation into the model for end stage liver disease score did not substantially add to the prediction of waiting list mortality. It was a well-designed study and the use of competitive risk analysis was particularly commendable given the nature of the cohort (patients on transplant waiting list). (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 3, 2018 Category: Gastroenterology Authors: Arka De, Akash Singh, Sunita Kumari, Virendra Singh Tags: Letter to the Editor Source Type: research

Reply to: “May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?” and “Has the time come for using MELD-Sarcopenia score?”
We would like to thank Lucidi et al.1 and De et al.2 for their interest in our work3 and for highlighting some challenging issues regarding the impact of low skeletal muscle mass in liver transplant candidates with cirrhosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 3, 2018 Category: Gastroenterology Authors: Jeroen L.A. van Vugt, Louise J.M. Alferink, S. Buettner, Herold J. Metselaar, Jan N.M. IJzermans Tags: Letter to the Editor Source Type: research

Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection
Occult hepatitis B virus (HBV) infection (OBI) refers to the presence of intrahepatic HBV DNA in the absence of detectable hepatitis B surface antigen (HBsAg) [1]. OBI is secondary to overt HBV infections; it guarantees the persistence of the virus in a cryptic form protected from the immune response of the host. The virological key is the covalently closed circular DNA (cccDNA), an HBV DNA form generated as a plasmid-like episome from the protein-linked relaxed circular DNA genome; it resides in the nucleus of infected cells and gives rise to progeny viral sequences acting as a transcription template for all viral RNAs [2...
Source: Journal of Hepatology - April 2, 2018 Category: Gastroenterology Authors: Gian Paolo Caviglia, Maria Lorena Abate, Francesco Tandoi, Alessia Ciancio, Antonio Amoroso, Mauro Salizzoni, Giorgio Maria Saracco, Mario Rizzetto, Renato Romagnoli, Antonina Smedile Source Type: research

EASL Clinical Practice Guidelines on hepatitis E virus infection
Infection with hepatitis E virus (HEV) is a significant cause of morbidity and mortality, representing an important global health problem. Our understanding of HEV has changed completely over the past decade. Previously, HEV was thought to be limited to certain developing countries. We now know that HEV is endemic in most high-income countries and is largely a zoonotic infection. Given the paradigm shift in our understanding of zoonotic HEV and that locally acquired HEV is now the commonest cause of acute viral hepatitis in many European countries, the focus of these Clinical Practice Guidelines will be on HEV genotype 3 (...
Source: Journal of Hepatology - March 30, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Tags: Clinical Practice Guidelines Source Type: research

Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure
Acute liver failure is a rapidly progressive, life-threatening deterioration of liver function that results in altered neurological state and coagulopathy. The only treatment that improves the outcome of acute liver failure is emergency liver transplantation. Because liver transplantation has limitations related to invasiveness, limited donor availability and high mortality, therapies for acute liver failure are urgently needed. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 26, 2018 Category: Gastroenterology Authors: Rosa Ferriero, Edoardo Nusco, Rossella De Cegli, Annamaria Carissimo, Giuseppe Manco, Nicola Brunetti-Pierri Tags: Research Article Source Type: research

Drug-induced chronic liver injury
The authors received no financial support to produce this manuscript (Table 1). (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 26, 2018 Category: Gastroenterology Authors: Lara Dakhoul, Marwan Ghabril, Naga Chalasani Tags: Hepatology Snapshot Source Type: research

Pyruvate dehydrogenase complex and lactate dehydrogenase as targets for therapy of acute liver failure.
Acute liver failure is a rapidly progressive, life-threatening deterioration of liver function that results in altered neurological state and coagulopathy. The only treatment that improves the outcome of acute liver failure is emergency liver transplantation. Because liver transplantation has limitations related to invasiveness, limited donor availability and high mortality, developing therapies for acute liver failure is urgently needed. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 26, 2018 Category: Gastroenterology Authors: Rosa Ferriero, Edoardo Nusco, Rossella De Cegli, Annamaria Carissimo, Giuseppe Manco, Nicola Brunetti-Pierri Source Type: research

Drug-induced chronic liver injury
The authors received no financial support to produce this manuscript (Table 1). (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 26, 2018 Category: Gastroenterology Authors: Lara Dakhoul, Marwan Ghabril, Naga Chalasani Tags: Hepatology Snapshot Source Type: research

Pyruvate dehydrogenase complex and lactate dehydrogenase as targets for therapy of acute liver failure.
Acute liver failure is a rapidly progressive, life-threatening deterioration of liver function that results in altered neurological state and coagulopathy. The only treatment that improves the outcome of acute liver failure is emergency liver transplantation. Because liver transplantation has limitations related to invasiveness, limited donor availability and high mortality, developing therapies for acute liver failure is urgently needed. (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 26, 2018 Category: Gastroenterology Authors: Rosa Ferriero, Edoardo Nusco, Rossella De Cegli, Annamaria Carissimo, Giuseppe Manco, Nicola Brunetti-Pierri Source Type: research